Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Operations: 2022-2025

Historic Cash from Operations for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to -$5.8 million.

  • Day One Biopharmaceuticals' Cash from Operations fell 111.44% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.6 million, marking a year-over-year decrease of 33.68%. This contributed to the annual value of -$78.1 million for FY2024, which is 46.81% up from last year.
  • Day One Biopharmaceuticals' Cash from Operations amounted to -$5.8 million in Q3 2025, which was up 76.60% from -$24.8 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Cash from Operations high stood at $50.8 million for Q3 2024, and its period low was -$59.0 million during Q1 2025.
  • Moreover, its 3-year median value for Cash from Operations was -$37.1 million (2023), whereas its average is -$28.6 million.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Cash from Operations spiked by 236.93% in 2024 and then plummeted by 111.44% in 2025.
  • Quarterly analysis of 4 years shows Day One Biopharmaceuticals' Cash from Operations stood at -$35.3 million in 2022, then dropped by 17.17% to -$41.4 million in 2023, then grew by 27.47% to -$30.0 million in 2024, then slumped by 111.44% to -$5.8 million in 2025.
  • Its last three reported values are -$5.8 million in Q3 2025, -$24.8 million for Q2 2025, and -$59.0 million during Q1 2025.